Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emmanuel Aris

Showing results (11-20 of 40) with videos related to

Pageof 4
Sort By:
Vaccine|March 3, 2020
The adult vaccination landscape in the United States during the Affordable Care Act era: Results from a large retrospective database analysisEmmanuel Aris, Marion Montourcy, Elizabeth Esterberg, et al.
Human Vaccines & Immunotherapeutics|December 2, 2017
An analysis of factors associated with influenza, pneumoccocal, Tdap, and herpes zoster vaccine uptake in the US adult population and corresponding inter-state variabilityElizabeth M La, Laurel Trantham, Samantha K Kurosky, et al.
The Pediatric Infectious Disease Journal|January 24, 2013
Antibody persistence for up to 5 years after a fourth dose of Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine (HibMenCY-TT) given at 12-15 months of ageGary S Marshall, Mark Blatter, Colin Marchant, et al.
BMC Medical Research Methodology|February 16, 2021
Causal inference concepts applied to three observational studies in the context of vaccine development: from theory to practiceEmilia Gvozdenović, Lucio Malvisi, Elisa Cinconze, et al.
Open Forum Infectious Diseases|June 5, 2024
The Incidence of Skin and Soft Tissue Infections in the United States and Associated Healthcare Utilization Between 2010 and 2020Venanzio Vella, Dominique Derreumaux, Emmanuel Aris, et al.
Epidemiology and Infection|May 26, 2026
Incidence of skin and soft tissue infections in England: 11-year retrospective studyVenanzio Vella, Dominique Derreumaux, Emmanuel Aris, et al.
Human Vaccines|February 11, 2011
Co-administration of a novel Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine does not interfere with the immune response to antigens contained in infant vaccines routinely used in the United StatesGary S Marshall, Colin D Marchant, Mark Blatter, et al.
The Journal of Infectious Diseases|August 12, 2025
Real-world effectiveness of the adjuvanted recombinant zoster vaccine in ≥50-year-old adults with autoimmune diseasesDagna Constenla, Germain Lonnet, Emmanuel Aris, et al.
The Pediatric Infectious Disease Journal|December 26, 2009
Randomized trial to assess immunogenicity and safety of Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine in infantsColin D Marchant, Jacqueline M Miller, Gary S Marshall, et al.
Vaccine|May 3, 2016
Phase I, randomized, observer-blind, placebo-controlled studies to evaluate the safety, reactogenicity and immunogenicity of an investigational non-typeable Haemophilus influenzae (NTHi) protein vaccine in adultsGeert Leroux-Roels, Pierre Van Damme, Wouter Haazen, et al.
Pageof 4

Showing results (11-20 of 40) with videos related to

Sort By:
Pageof 4
Vaccine|March 3, 2020
The adult vaccination landscape in the United States during the Affordable Care Act era: Results from a large retrospective database analysisEmmanuel Aris, Marion Montourcy, Elizabeth Esterberg, et al.
Human Vaccines & Immunotherapeutics|December 2, 2017
An analysis of factors associated with influenza, pneumoccocal, Tdap, and herpes zoster vaccine uptake in the US adult population and corresponding inter-state variabilityElizabeth M La, Laurel Trantham, Samantha K Kurosky, et al.
The Pediatric Infectious Disease Journal|January 24, 2013
Antibody persistence for up to 5 years after a fourth dose of Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine (HibMenCY-TT) given at 12-15 months of ageGary S Marshall, Mark Blatter, Colin Marchant, et al.
BMC Medical Research Methodology|February 16, 2021
Causal inference concepts applied to three observational studies in the context of vaccine development: from theory to practiceEmilia Gvozdenović, Lucio Malvisi, Elisa Cinconze, et al.
Open Forum Infectious Diseases|June 5, 2024
The Incidence of Skin and Soft Tissue Infections in the United States and Associated Healthcare Utilization Between 2010 and 2020Venanzio Vella, Dominique Derreumaux, Emmanuel Aris, et al.
Epidemiology and Infection|May 26, 2026
Incidence of skin and soft tissue infections in England: 11-year retrospective studyVenanzio Vella, Dominique Derreumaux, Emmanuel Aris, et al.
Human Vaccines|February 11, 2011
Co-administration of a novel Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine does not interfere with the immune response to antigens contained in infant vaccines routinely used in the United StatesGary S Marshall, Colin D Marchant, Mark Blatter, et al.
The Journal of Infectious Diseases|August 12, 2025
Real-world effectiveness of the adjuvanted recombinant zoster vaccine in ≥50-year-old adults with autoimmune diseasesDagna Constenla, Germain Lonnet, Emmanuel Aris, et al.
The Pediatric Infectious Disease Journal|December 26, 2009
Randomized trial to assess immunogenicity and safety of Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine in infantsColin D Marchant, Jacqueline M Miller, Gary S Marshall, et al.
Vaccine|May 3, 2016
Phase I, randomized, observer-blind, placebo-controlled studies to evaluate the safety, reactogenicity and immunogenicity of an investigational non-typeable Haemophilus influenzae (NTHi) protein vaccine in adultsGeert Leroux-Roels, Pierre Van Damme, Wouter Haazen, et al.
Pageof 4